«BioEq» recruits for patients with nonresectable or metastatic melanoma to participate in a phase II clinical study.
Study medication: monoclonal anti-PD-1 antibody.
Clinical study length: Maximum 69 weeks, including screening (up to 4 weeks), clinical study therapy (up to 53 weeks), further monitoring (up to 12 weeks)
We invite adult male and female patients with:
- Histological verificate nonresectable or metastatic melanoma
- Elementary educed frequent or metastatic melanoma
- Disease progression after previous system therapy